Although CA125 and another popular tumor marker, Human Epidydimis protein 4 (HE4), were assayed in pregnant women, the prognostic value of those markers used alone or in combination (ROMA test, i.e., the Risk of Malignancy Algorithm) in discriminating adnexal tumors in pregnancy is unknown [8,9,10]. This evidence concerns the gene WFDC2 and neoplasm.